Shares of Johnson & Johnson (JNJ) climbed 0.35% to $273.27 after the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO for certain advanced forms of head and neck cancer. The stock gained $0.95 on the session, recovering from intraday lows near $266.50 after earlier selling pressure. The approval expands the company's oncology portfolio, although the authorized use excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.

FDA Approves RYBREVANT FASPRO With HPV-Related Exclusion

The FDA granted accelerated approval for RYBREVANT FASPRO as a treatment for adults with recurrent or metastatic head and neck cancer. Accelerated approval is a regulatory pathway that allows earlier authorization for serious conditions based on measures such as tumor response, with continued approval tied to confirmation of clinical benefit in follow-up trials. To qualify, patients must have experienced disease progression following platinum-based chemotherapy and anti-PD-(L)1 therapy. The indication specifically excludes patients with HPV-associated oropharyngeal squamous cell carcinoma, a subgroup identified through p16 immunohistochemistry testing, a standard pathology method for characterizing HPV-related tumors.

The HPV exclusion applies specifically to oropharyngeal tumors associated with the virus. The therapy itself targets EGFR and MET, two pathways involved in cancer growth and progression, and is administered as a subcutaneous injection that takes approximately five minutes to complete, a delivery format that generally requires less administration time than conventional intravenous infusions.

The FDA had previously granted the therapy Breakthrough Therapy Designation in February 2026, followed by Priority Review in July 2026. The approval marks the product's first authorized indication beyond non-small cell lung cancer and widens the range of treatment options available to patients whose disease has progressed after earlier therapies.

OrigAMI-4 Trial Reports 42% Response Rate

The FDA based its decision on data from the ongoing Phase 1b/2 OrigAMI-4 clinical trial. Researchers evaluated 102 patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Consistent with the approved indication, the study excluded patients with HPV-positive oropharyngeal squamous cell carcinoma.

The trial recorded a confirmed overall response rate of 42%, including complete responses in 15% of patients. A further 28% of patients achieved partial responses, and 56% of those who responded maintained their benefits for more than six months. The findings supported accelerated approval on the basis of measurable and durable tumor responses.

Safety data identified adverse reactions including rash, fatigue, nail toxicity, stomatitis, and edema. Serious adverse reactions affected 39% of patients, while fatal adverse reactions occurred in 6%. The ongoing Phase 3 OrigAMI-5 trial will further evaluate the therapy's clinical benefits to support continued approval, the confirmatory step that determines the indication's long-term standing under the accelerated pathway.

Approval Expands Johnson & Johnson's Oncology Portfolio

The regulatory decision strengthens Johnson & Johnson's position in advanced cancer treatment. RYBREVANT FASPRO introduces dual EGFR and MET targeting for eligible patients who have limited treatment alternatives, and it extends the company's existing amivantamab franchise into another cancer category. Regulatory milestones of this kind are a central way drugmakers broaden established oncology franchises across multiple tumor types.

Head and neck squamous cell carcinoma affects the tissues lining the mouth, throat, and other nearby structures. Advanced cases are often difficult to treat once patients have undergone chemotherapy and immunotherapy. The new indication therefore addresses a specific group of patients whose disease progresses despite previous treatment.

The stock's intraday recovery reflected renewed buying activity following earlier selling pressure. The FDA decision adds another regulatory milestone to the company's broader oncology development strategy, and Johnson & Johnson will continue evaluating RYBREVANT FASPRO through clinical trials as it expands its cancer treatment portfolio.

This article was originally published on Blockonomi.